Stifel analyst Benjamin Burnett reiterated a Buy rating on Fate Therapeutics (NASDAQ: FATE) following NKTX's report of latest AML/NHL data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE